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ABSTRACT
Background. Nonoperative but systemic therapy as first-
line management is offered to some patients with breast
cancer (BC) who have assumed limited life expectancy,
such as older women or those who have distant metastases
at initial presentation. We evaluated rates of and predicting
factors for success and failure of this therapy approach.
Methods. Seventy-five patients who were initially treated
only systemically, and cases in which local control while
avoiding surgery was the intended long-term therapy goal
were analyzed. Additionally, two stage-dependent sub-
groups were distinguished (A: stage I-III, n = 31; B: stage
IV, n = 44). Failure of therapy was defined as when sec-
ondary surgery had to be performed due to locoregional
progression or in case of no surgery when severe locore-
gional clinical signs/symptoms were observed during the
further course.
Results. Patients in group A were older than those in
group B (81 vs. 67.5 years; P \ 0.001) and showed an
increased survival (5-year rates: 40.2% vs. 24.3%). In 24
patients of the entire cohort (32%), secondary surgery had
to be performed; surgery was performed more often in
group A (58.1% vs. 13.6%). In the cases in which no
surgery was performed (n = 51), 11 women (21.6%) suf-
fered from severe locoregional symptoms in the palliative
situation (A: n = 1; B: n = 10). Although the presence of
stage IV was a significant factor for therapy success (odds
ratio (OR), 2.59; 95% confidence interval (CI), 0.95–7.05;
P = 0.039), skin involvement was associated with failure
of therapy (OR, 3.57; 95% CI, 1.16–11.11; P = 0.031).
Conclusions. Nonoperative treatment may be offered to
selected patients with BC who have assumed limited life
expectancy. These women must be openly informed that
this approach is not successful in nearly half of the cases.
Surgery is the central component of curative treatment
and for local control of breast cancer. There are, however, a
great many situations in which surgery is not performed as
initial treatment. Such situations occur when patients refuse
surgery against medical advice or when the tumor is
inoperable due to excessive locoregional spread or in the
case when patients are deemed unfit for surgical interven-
tion due to frailty or comorbidity. Furthermore, in some
patients with distant metastatic disease at initial presenta-
tion, surgery is not considered to be beneficial when a
limited survival time is expected. The impact of nonoper-
ative management has been evaluated for several
subgroups, such as older women, in case of patients’
refusal, and women who present with stage IV breast
cancer.1–14 These studies consistently showed that surgery
is associated with improved local control and survival.
In our opinion, the differentiation made by other authors
between the above-mentioned subgroups of patients is not
necessarily sensible from a clinician’s view and is partly
artificial.1–6,8–14 If patients and physicians agree on non-
operative treatment as initial breast cancer management,
the basic approach of this concept is to expect/hope for
long-term control of locoregional disease with systemic
therapy. In most cases, the decision for this treatment
option is made with the assumption of a patient’s short life
expectancy. This is the case in older patients and/or
patients with severe comorbidity, as well as in patients who
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are clearly in a palliative situation due to distant metasta-
ses. That this separation is artificial becomes apparent
when one emphasizes the common goal of nonoperative
management; we defined this therapy approach as suc-
cessful where local control could be reached by palliative
systemic therapy and no clinically relevant locoregional
progression developed.
We recognized the similar conception of the nonopera-
tive patient group and examined, on the basis of the data of
a prospective Swiss breast cancer database during a 20-
year period, for the first time in literature, the group of
patients in its entirety who were initially treated only sys-
temically and without surgical intervention and highlight
the conceptual similarities of these patients who are
otherwise considerably heterogeneous in terms of age,
clinical appearance, tumor characteristics, therapeutic
options, prognosis, and individual perceptions. Thus, in
addition to the entire group, it is still important to evaluate
the above-mentioned stage-defined subgroups separately.
Particularly, a comparison between these two subgroups
has not been conducted before. Furthermore, we evaluate
rates of and predicting factors for success and failure of this
particular therapy approach.
PATIENTS AND METHODS
The prospective relational Basel Breast Cancer Database
(BBCD) includes all newly diagnosed primary invasive
breast cancer cases treated at the University Women’s
Hospital Basel, Switzerland, since 1990. Data were recor-
ded continuously from the medical files. For this study,
data from patients treated through 2009 were analyzed
(n = 1,495).
It was the goal of our study to evaluate patients 1) who
did not undergo surgery as initial therapy but were treated
systemically and 2) where local control while avoiding
surgery was the intended long-term therapy goal.
Therefore, patients who had neoadjuvant therapy
(n = 68; 4.6% of the entire BBCD cohort), i.e., where the
therapy concept implied surgery after a defined period of
preoperative systemic therapy, were excluded from analy-
sis. Second, three women (0.2%) who refused all therapy
options, i.e., in which the natural course of breast cancer
could be studied, were not considered. Third, we excluded
12 patients who initially refused an operation, started a
systemic therapy but changed their opinion within 8 weeks,
and underwent surgical intervention.
In the end, 75 nonoperative patients (5% of the BBCD
cohort) who met the aforementioned inclusion criteria
comprise the cohort of this study. We provided complete
outcome information for these women. They were followed
until death or, if they remained alive and disease-free, for a
maximum of 17 years. The median follow-up duration
after breast cancer diagnosis was 25 (range, \1–206)
months. At the time of data collection in November 2010,
the outcome data of patients still alive was not older than
6 weeks.
For this study, information on tumor classification was
reported according to the current AJCC/UICC TNM
guidelines.15,16 Twenty-eight patients showed skin
involvement. From these, 21 had noninflammatory skin
involvement (T4b) showing the classical clinical sign of
ulceration, and 7 patients presented with inflammatory
carcinoma.17
In most cases (n = 69), the diagnosis of invasive car-
cinoma was confirmed by core needle biopsy; in six cases
diagnosis was made by fine-needle aspiration biopsy.
Hormonal receptor assay and assessment of histopathologic
grading according to the Nottingham modification of the
Scarff-Bloom-Richardson grading scheme also were per-
formed (Table 1). Additional biological predictive factors
(e.g., overexpression of HER-2/neu, p53, EGFR), which
eventually may prove to be more reliable index measures
of tumor aggressiveness, were not performed on a regular
basis during the 1990s; therefore, information on these
factors was not available for all patients and were not taken
into account in the final analysis. Tumor size was assessed
clinically (cT classification) by imaging and/or physical
examination.
Each patient underwent a workup to determine staging,
including a recording of clinical history, physical exami-
nation, routine blood studies and additional radiologic
studies (e.g., chest x-ray, sonography of the liver, nuclear
bone scans, computed tomography, magnetic resonance
imaging) as needed to exclude metastatic disease. There
was no standard nonoperative therapeutic approach during
the study period (Table 2). Treatment was selected based
on the individual situation taking comorbid conditions and
patients’ perceptions and compliance into consideration.
In this study, in addition to the entire study cohort
(n = 75), we analyzed two subgroups, which were distin-
guished by the disease stage at initial presentation: (1)
patients who did not show distant metastases (stage I–III;
n = 31); (2) patients who had distant metastases (stage IV;
n = 44).
Furthermore, we analyzed how often the goal of non-
operative management was met and which factors were
associated with a successful therapy. We defined the
therapy goal as reached when the treatment managed to
control the locoregional disease and long-term avoidance
of surgery was assured. We defined the following situations
as failure to meet the therapy goal:
– Secondary surgery had to be performed due to
progressive disease
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– In case of no surgery, the development of advanced
locoregional clinical morbidity that significantly
impaired quality of life, such as large ulcerating and
fungating lesions (to the point of cancer en cuirasse) or
severe lymphedema.
Data collection methods and study design were
approved by the institutional review board.
Statistical Methods
Using the Kaplan–Meier method, overall survival (OS)
was calculated from the date of diagnosis to the date of
death or the time of last follow-up for patients still living.
Statistical differences between the survival curves of the
study subgroups were analyzed using the log-rank test. To
predict factors contributing to attain the therapy goal,
logistic regression was performed. Comparisons between
nominal parameters were made using the Fisher’s exact
test. Comparisons between metric parameters were made
with the Wilcoxon rank-sum test. A P value \0.05 was
considered significant. Statistical analyses were performed
with R Development Core Team software, version 2.11.1
(Vienna, Austria).
RESULTS
The clinicopathologic, treatment, and outcome charac-
teristics of the 75 patients who had a nonoperative therapy
approach are summarized in Tables 1 and 2. The median
age of 73 years of these patients was 13 years older than
that of the entire cohort of patients recorded in the BBCD;
patients in group A were significantly older than those in
group B (81 vs. 67.5 years; P \ 0.001). Clinically assessed
mean tumor size was 52.6 mm in the entire cohort; patients
in group A had significantly smaller tumors (35.1 vs.
65.2 mm; P = 0.002).
TABLE 1 Clinicopathologic
characteristics of 75 patients
with breast cancer who had
primary medical and
nonoperative management as
initial treatment
ER estrogen receptor
a AJCC/UICC TNM
classification15,16
b TX: occult carcinoma (TX N3
M1)
c In cases with inflammatory
carcinoma, tumor size was not
recorded
Variable Entire study
cohort
Group A
(stage I–III)a
Group B
(stage IV)a
No. of patients 75 31 44
Age at diagnosis [yr]
Median (range) 73 (38–92) 81 (52–92) 67.5 (38–92)
TNM stage at initial diagnosisa
I 8 (10.7) 8 (25.8) –
II 15 (20) 15 (48.4) –
III 8 (10.7) 8 (25.8) –
IV 44 (58.6) – 44
Tumor size at initial diagnosis, clinically measured [mm]
Mean/median (range) 52.6/32 (11–220) 35.1/25 (11–150) 65.2/50 (14–220)
Tumor category, clinical classificationa
TXb 1 (1.3) – 1 (2.2)
T1c (11–20 mm) 14 (18.7) 9 (29) 5 (11.4)
T2 (21–50 mm) 25 (33.3) 15 (48.4) 10 (22.7)
T3 ([ 50 mm) 7 (9.3) – 7 (15.9)
T4b 20 (26.7) 4 (12.9) 16 (36.4)
T4c 1 (1.3) – 1 (2.2)
T4d (inflammatory carcinoma)c 7 (9.3) 3 (9.7) 4 (9.1)
Histologic subtype
Ductal invasive 56 (74.7) 24 (74.4) 32 (72.7)
Lobular invasive 13 (17.3) 4 (12.9) 9 (20.5)
Other types 6 (8) 3 (9.7) 3 (6.8)
Hormone receptor status
ER positive 51 (68.0) 23 (74.2) 28 (63.6)
Not known 6 (8) 3 (9.7) 3 (6.8)
Grading
G1/2: well/moderately differentiated 36 (48) 15 (48.4) 21 (47.7)
G3: poorly differentiated 26 (34.7) 10 (32.3) 16 (36.4)
Not known/not applicable 13 (17.3) 6 (19.3) 7 (15.9)
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OS of the entire study cohort and the two subgroups is
shown in Fig. 1; the 5- and 10-year adjusted survival rates
of the entire cohort were 30.9% and 11.3%, respectively.
Compared with group B, the patients in group A had a
significantly increased survival (5-year rates: 40.2% vs.
24.3%; 10-year rates: 16.1% vs. 7.3%).
Duration of first-line systemic therapy was similar in
both subgroups (22.4 vs. 25.3 months). Most patients
responded positively after starting medical treatment (A:
87.1% vs. B: 77.3%). In 24 patients of the entire cohort
(32%), a secondary surgery had to be performed due to
locoregional progressive disease. Surgical intervention was
performed more often in group A (58.1% vs. 13.6%). In the
cases where no surgery was performed, 11 women (21.6%)
suffered from severe locoregional symptoms and ailments
in the palliative situation. Ten of these had stage IV disease
at initial presentation (group B). Our defined therapy goal
of nonoperative but systemic therapy as first-line man-
agement in breast cancer (no surgery; no or only minor
locoregional clinical signs and symptoms at last follow-up)
was met in approximately half of the patients. Despite this
high local failure rate, approximately one-third of these
patients achieved remission for more than 18 months by
first-line therapy (data not shown).
The independent factors for a successful therapy also
were analyzed by performing a multivariate analysis,
which took into account tumor size, noninflammatory skin
involvement, and metastatic disease at initial presentation
(Table 3). Although the presence of stage IV (subgroup B)
was a significant factor for therapy success (odds ratio
TABLE 2 Treatment and
outcome characteristics of 75
patients with breast cancer who
had primary medical and
nonoperative management as
initial treatment
EC endocrine therapy; CT
chemotherapy, including
trastuzumab; NED no evidence
of disease
a Definition of last follow-up:
(1) for patients who are alive:
the status of the most previous
consultation; (2) for patients
who died: status in the prefinal
situation
b For analysis of long-term
survivors, only patients who
were diagnosed before 2005,
i.e., who had a potential
observation time of at least
5 years, were included (entire
cohort, n = 47; group A,
n = 22; group B, n = 25)
Variable Entire
study cohort
Group A
(stage I-III)1
Group B
(stage IV)1
Number of patients 75 31 44
Primary medical therapy
Endocrine therapy (EC) 48 (64.0) 28 (90.3) 20 (45.5)
Chemotherapy (CT) 7 (9.3) – 7 (15.9)
Combination: EC ? CT 20 (26.7) 3 (9.7) 17 (38.6)
Duration of primary medical therapy
Mean/median [mo] (range) 24.1/14 (1–174) 22.4/15 (3–118) 25.3/10 (1–174)
Initial positive response 61 (81.3) 27 (87.1) 34 (77.3)
Secondary surgery performed 24 (32.0) 18 (58.1) 6 (13.6)
In the case no surgery was performed:
Locoregional situation at last follow-upa
51 13 38
No clinical signs 27 (52.9) 11 (84.6) 16 (42.1)
Minor clinical signs 13 (25.5) 1 (7.7) 12 (31.6)
Major clinical signs 11 (21.6) 1 (7.7) 10 (26.3)
Further clinical course
No morbidity 27 (36.0) 18 (58.1) 9 (20.5)
Locoregional progression 1 (1.3) 1 (3.2) –
Systemic progression 25 (33.3) 8 (25.8) 17 (38.6)
Locoregional ? systemic progression 22 (29.3) 4 (12.9) 18 (40.9)
Therapy goal reached: no surgery, no or only
minor locoregional clinical signs/symptoms
at last follow-upa
40 (53.3) 12 (38.7) 28 (63.6)
Outcome status
Died of metastatic disease 43 (57.3) 11 (35.5) 32 (72.7)
Died of other causes 15 (20) 13 (41.9) 2 (4.5)
Alive, NED 6 (8) 5 (16.1) 1 (2.2)
Alive with breast cancer 11 (14.7) 2 (6.5) 9 (20.5)
Survival time (yr)
\1 17 (22.7) 3 (9.7) 14 (31.8)
[3b 25 (53.2) 16 (72.7) 9 (36)
[5b 19 (40.4) 11 (50) 8 (25)
[10b 5 (10.6) 4 (18.2) 1 (4)
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(OR), 2.59; 95% confidence interval (CI), 0.95–7.05;
P = 0.004), skin involvement was associated with failure
of therapy (OR, 3.57; 95% CI, 1.16–11.11; P = 0.031).
DISCUSSION
Atkin et al. reported reasons for a policy of nonoperative
management in patients with nonmetastatic breast cancer
and distinguished between the three categories: ‘‘inopera-
ble’’ (1.3% of their entire breast cancer cohort), ‘‘unfit for
surgery’’ (6%), and ‘‘refused surgery’’ (1.5%).6 We think
that this compartmentation is too rigid and that in most
cases there is an overlap between the three categories. In
our opinion, only very few carcinomas are actually inop-
erable. Even in most cases with locally advanced disease,
surgical intervention is feasible. However, one must
question whether rather complex reconstructive procedures
to cover the chest wall defect are justified in every case. In
our cohort, we considered only three cases to be inopera-
ble. These were cases with a clinically assessed tumor size
between 15 and 22 cm; all showed noninflammatory skin
involvement and one of them had additional deep infiltra-
tion of the chest wall (T4c). Furthermore, we think that by
applying the current standards of anesthesia and postop-
erative surveillance today, it is possible for elderly and frail
women to undergo safe breast surgery that has relatively
little associated morbidity.18 When ‘‘refused surgery’’ is
listed as a separated category for reasons in nonoperative
management, one could assume that a patient’s refusal for
surgery is the result of a confrontation between patient and
physician. This is not so in our experience. More often is
the case that patients in oncological consultations tend to
be wary and reluctant toward an operation. In further dis-
cussions, the physician can address the anxieties and
reservations of the patients. Factors, such as average life
expectancy, presence of comorbidities, and an analysis of
potential treatment benefits versus risks of the proposed
treatment strategy, must be carefully weighed and the
option of a conservative nonoperative management can be
offered to patients.19 It must be taken into account that,
especially for older patients or those suffering from an
incurable disease, ‘‘classical’’ hard medical facts, such as
disease-specific and progression-free survival, are only one
component of total care. Whereas physicians tend to focus
on physical aspects, some patients and families view their
situation with broader psychosocial and spiritual meaning,
shaped by a lifetime of experiences.20 The priorities of
these women often lie more with retaining their current life
circumstances and their quality of life plays a more sig-
nificant role in determining their treatment options rather
than aiming solely for curative treatment.21 In our experi-
ence, in the majority of cases, nonoperative management is
the result of shared decision-making and clear communi-
cation that acknowledges the values and preferences of
patients and their families and not the patient’s categorical
refusal of medical advice. Before starting nonoperative
management, it is usually agreed that the effect of systemic
treatment should be monitored. An operation could still be
considered in the case of subsequent locoregional tumor
progression.
Randomized, clinical trials comparing surgery with
tamoxifen in elderly nonmetastatic patients have shown
that treatment solely with tamoxifen led to worse survival
and failed to control the disease in most patients (45–81%);
thus, a high proportion required surgery after they devel-
oped local disease progression.1,2,4,5 In our study, we found
a treatment failure of 61% in subgroup A. Most of these
patients (58%) required secondary surgery. Approximately
one-third of these patients who had nonmetastatic disease
at initial diagnosis died subsequently of breast cancer. This
supports the assumption that residual or recurrent local
disease could be a source of distant metastases.10 The
conclusions from studies that evaluated nonoperative
management in nonmetastatic breast cancer can be applied
FIG. 1 Overall survival of 75 patients with breast cancer who had
primary medical and nonoperative management as initial treatment.
(1) entire study cohort, n = 75; (2) subgroup A: disease stage I–III,
n = 31; (3) subgroup B: stage IV, n = 44
TABLE 3 Multiple logistic regression predicting the factors that
influence the successful attainment of the therapy goal in primary
medical and nonoperative management as initial treatment (no sur-
gery, no or only minor clinical signs/symptoms at last follow-up)
Variable OR (95% CI) P value
Tumor size 0.58 (0.31–1.08) 0.162
Non-inflammatory skin involvement 0.28 (0.09–0.86) 0.031
Stage IV at initial diagnosis 2.59 (0.95–7.05) 0.004
OR odds ratio; CI confidence interval
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to patients with stage IV breast cancer; also in this situa-
tion, surgical treatment was found to be an independent
factor associated with improved survival.8–14 To our
knowledge, there is no study that has reported late surgery
after initial nonoperative management in this group of
patients. We found that the rate of 13.6% for late surgery in
subgroup B was significantly lower than that of patients
with nonmetastatic disease. However, one must strongly
counter that further avoidance of surgical intervention in
some patients in subgroup B led to the fact that 26.3% died
not only from metastatic disease but also suffered from
severe locoregional disease processes in the palliative sit-
uation. In accordance with Kenny et al., we found that
uncontrolled locoregional relapse was a rare occurrence in
subgroup A.4 In cases of uncontrolled locoregional pro-
gression, one must criticize the fact that the initial intention
to perform surgery in subsequent tumor progression was
not followed. One could assume that in metastatic patients
the willingness of oncologists and/or surgeons to revise the
nonoperative approach was low—to the disadvantage of
the patients. We believe that even in an incurable situation,
surgical intervention should be considered a useful pallia-
tion of agonizing pain and hygiene problems posed by
bulky, necrotic tumors.
Life expectancy is an important factor in the decision-
making process in the treatment of elderly and/or patients
with metastatic breast cancer.19 This fact is mirrored in
42% of patients in subgroup A (which is comprised mostly
of elderly women) who died of other causes than breast
cancer. In approximately half of these patients, no sec-
ondary surgery was performed and medical treatment
repressed or stabilized the disease, as intended, until death.
However, an accurate estimation of life expectancy is
difficult. In our study, only 9.7% of the patients in sub-
group A showed a survival time \ 12 months (Table 2).
This rate was considerably higher (31.8%) in patients with
distant metastases at initial presentation. Even when we
restricted this analysis to women C75 years who had died
during the observation period (i.e., who had completed
follow-up), the median follow-up time was 20.5 months in
subgroup B and 36.5 months in group A. The shorter sur-
vival time might contribute to the fact that in patients of
subgroup B a successful therapy goal was met more often.
At the other end of the spectrum of life expectancy are
long-term survivors. Analyzing only patients who had been
diagnosed up until 2005, i.e., who had a possible obser-
vation time of at least 5 years (Table 2), 68% of the
patients in subgroup A and 29% of patients in group B
survived longer than 5 years. Five patients from our entire
cohort even had a survival time longer than 10 years. One
of these five patients was a woman who was diagnosed
with stage IV breast cancer in 1995 who was treated with
chemo- and endocrine therapy. The patient is still alive
today (182 months after initial diagnosis) and has shown
no evidence of disease for more than 10 years, neither in
the nonoperated breast nor in the previously diagnosed
metastatic sites (bone, lung). This is one of the very few
cases, which refute the tenet that distant metastatic breast
cancer is incurable in all cases.22
In our opinion, there is a clear role for surgery in pre-
venting or palliating breast or chest wall symptoms, not
only for older women and those with severe comorbid
conditions, but also for patients in an incurable situation
with distant metastases. Some authors prefer a surgical
approach because it offers the maximum chance of local
control and surgery may be more difficult after subsequent
progression of disease.2,4 It is of great importance that
women are entirely involved in the decision-making pro-
cess concerning their treatment, and we acknowledge that
they have the full right to choose not to undergo surgery. In
accordance with other authors, we do not recommend
‘‘routine’’ breast surgery or definitive local treatment in all
women but offer solely standard systemic palliative treat-
ments for selected patients.1,5,9,10 These patients must
openly be informed that a nonoperative approach is not
successful in the nearly half of the cases and is generally
associated with poorer outcome. In cases of overt locore-
gional progression, the preferred path, however, should be
revised to avoid the complete loss of tumor control, which
might be associated with severe symptoms and wound
complications of breast and chest wall.
There are some limitations of our study that have to be
addressed. First, we cover a long period of time in which
therapy options have evolved considerably. Second, our
study is retrospective. We do not believe, however, that
this is necessarily a weak point. National Cancer Registries
often exclude patients treated conservatively, limiting their
validity for analysis in this group of patients. A clinical
database of a single institution, such as the one used in this
study, records data prospectively for all patients and pro-
vides solid follow-up data. The results in this series provide
insights into patients who were treated with a nonoperative
management. Future clinical trials are needed to further
evaluate this subgroup of patients, which represents
approximately 5–10% of all patients with breast cancer. In
a field that is strongly shaped by very individual percep-
tions and decisions of partly opinionated patients, a
randomized study is hardly possible.
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